维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

已收盘 07-21 16:08:06

63.850

-0.600

-0.93%

最高66.050	最低60.800	成交量75.35万
今开64.300	昨收64.450	日振幅8.15%
总市值127.06亿	流通市值126.42亿	总股本1.99亿
成交额4,737万	换手率0.38%	流通股本1.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":63.85,"timestamp":1784621286010,"preClose":64.45,"halted":0,"volume":753500,"delay":0,"changeRate":-0.009309542280837881,"floatShares":198000000,"shares":199000000,"eps":-1.4022507057716436,"marketStatus":"已收盘","change":-0.6,"latestTime":"07-21 16:08:06","open":64.3,"high":66.05,"low":60.8,"amount":47369472,"amplitude":0.081458,"askPrice":63.9,"askSize":900,"bidPrice":63.85,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.3640075047051443,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784683800000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":64.45,"openAndCloseTimeList":[[1784597400000,1784606400000],[1784610000000,1784620800000]],"volumeRatio":0.36295,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887","defaultTab":"news","newsList":[{"id":"1168059671","title":"一周港股牛熊榜 | 真健康医疗-B受手术机器人题材催化爆升74%，卓越睿新牵手阿里云涨逾40%；德适-B高估值回调近37%，钧达股份预亏拖累跌逾34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168059671","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168059671?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:24","pubTimestamp":1784280294,"startTime":"0","endTime":"0","summary":"总结全周（7月13日-7月17日），恒生指数涨387.12点或1.6%，恒生科技指数跌98.49点或2.09%。本周涨幅居前个股中，真健康医疗-B受手术机器人稀缺性及高端医疗器械政策催化，累计上涨74%；卓越睿新与阿里云合作推进AI教学及科研场景落地，本周上涨40.03%；维立志博-B因六项研究入选ESMO、核心管线进入优先审评，累计上涨29.21%。跌幅方面，德适-B在高估值及持续亏损压力下累计下跌36.94%；钧达股份预告上半年最高亏损2.7亿元，累计下跌34.83%；建滔积层板在PCB涨价线高位回落下累计下跌33.15%。","market":"hk","thumbnail":"https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","01888","06127","02889","02687","00148","02526","02697","03277","02865","09887"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651432957","title":"港股异动 | 维立志博-B(09887)再涨超11% 近3日股价累涨超三成 多项研究成果入选2026 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651432957","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651432957?lang=zh_cn&edition=full","pubTime":"2026-07-15 14:25","pubTimestamp":1784096755,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B再涨超11%，近三个交易日股价累涨超三成。截至发稿，涨11.45%，报67.15港元，成交额1.66亿港元。消息面上，近日，维立志博公布了2026年ESMO入选结果，已确认六项最新研究成果入选，其中最高规格口头报告两项，9月预计还有LBA入选。公司表示，这一里程碑标志着维利信的商业化时间表正式锁定，获批上市时间明确可期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK1161","HK0000252152.HKD","BK4588","BK4585","VXUS","09887","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651129589","title":"维立志博-B盘中涨超15% 核心管线LBL-024被纳入优先审评审批程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2651129589","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651129589?lang=zh_cn&edition=full","pubTime":"2026-07-14 11:41","pubTimestamp":1784000460,"startTime":"0","endTime":"0","summary":"　　维立志博-B早盘一度涨超15%，截至发稿，股价上涨6.39%，现报63.30港元，成交额1.67亿港元。　　7月10日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信单药治疗晚期经治肺外神经内分泌癌的生物制品上市许可申请，获国家药品监督管理局药品审评中心批准纳入优先审评审批程序。公司指，这一里程碑标志着维利信的商业化时间表正式锁定，获批上市时间明确可期。与此同时，维立志博正积极推进上市前的各项商业化准备工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-14/doc-inihtvuh8558402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651125132","title":"港股异动 | 维立志博-B(09887.HK)涨超13% ESMO多项研究成果入选 核心管线LBL-024被纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2651125132","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651125132?lang=zh_cn&edition=full","pubTime":"2026-07-14 10:23","pubTimestamp":1783995804,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","09887","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121474067","title":"维立志博-B（09887）六项研究成果入选2026年ESMO年会 两项获最高规格口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1121474067","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121474067?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:42","pubTimestamp":1783932120,"startTime":"0","endTime":"0","summary":"2026年7月13日，维立志博-B发布自愿公告称，其六项最新研究成果已获欧洲肿瘤内科学会年会接收，其中两项被选为最高规格的“优选口头报告”，其余四项将进行壁报展示。此外，公司同获“最新突破摘要”资格，并计划于2026年9月提交完整摘要。ESMO 2026年会将于2026年10月23日至27日在西班牙马德里举行。公告同时回顾，公司此前披露的维利信一线非小细胞肺癌研究，已入选2026年世界肺癌大会口头报告，相关摘要预计于2026年8月19日在WCLC官网公布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651194274","title":"维立志博-B(09887)：多项研究成果入选2026 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651194274?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:38","pubTimestamp":1783931924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，其六项最新研究成果入选2026年欧洲肿瘤内科学会年会。此外，公司已获授最新突破摘要资格，并将于2026年9月提交完整LBA。LBA则为针对被视为具有突破性且有望改变临床实践的最新临床研究进展而设的专门类别。公司此前亦公布，维利信用于治疗一线非小细胞肺癌的研究已入选于2026年9月举行的世界肺癌大会上进行口头报告。摘要全文预期将于2026年8月19日在WCLC官方网站上发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","09887","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651199676","title":"Gate 港股高弹性标的活跃，维立志博-B大涨近 30% 领涨涨幅榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2651199676","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651199676?lang=zh_cn&edition=full","pubTime":"2026-07-13 15:15","pubTimestamp":1783926923,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Gate 行情数据显示，港股市场整体呈现震荡分化，部分高弹性标的逆势走强。Gate 平台港股涨幅榜前三分别为：维立志博-B 大涨 29.90%，现报 HK$64.85；广联科技控股上涨 21.70%，现报 HK$4.99；中国华君上涨 20.66%，现报 HK$1.46。\n\n ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2276190","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","VXUS","HK0000500386.USD","BK4585","BK4588","KCAI","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651816037","title":"维立志博-B午前涨超27% 维利信®上市申请纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2651816037","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651816037?lang=zh_cn&edition=full","pubTime":"2026-07-13 11:27","pubTimestamp":1783913220,"startTime":"0","endTime":"0","summary":"　　维立志博-B午前涨超27%，截至发稿，股价上涨27.40%，现报63.60港元，成交额2.02亿港元。　　7月10日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信单药治疗晚期经治肺外神经内分泌癌的生物制品上市许可申请，获国家药品监督管理局药品审评中心批准纳入优先审评审批程序。　　公司指，这一里程碑标志着维利信的商业化时间表正式锁定，获批上市时间明确可期。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9119990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000252160.HKD","09887","BK1161","HK0000500386.USD","IPOS","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651167228","title":"港股异动 | 维立志博-B(09887.HK)涨超26% 维利信®上市申请纳入优先审评 商业化进程全面提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2651167228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651167228?lang=zh_cn&edition=full","pubTime":"2026-07-13 11:02","pubTimestamp":1783911745,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189644529","title":"优先审评资格授予PD-L1/4-1BB双特异性抗体Opamtistomig，加速商业化进程并应对上皮样肉瘤未满足的临床需求","url":"https://stock-news.laohu8.com/highlight/detail?id=1189644529","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189644529?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:55","pubTimestamp":1783673720,"startTime":"0","endTime":"0","summary":"PD-L1/4-1BB双特异性抗体Opamtistomig获得优先审评资格，此举将显著加速该药物的商业化进程，并为上皮样肉瘤患者群体中存在的未满足临床需求提供潜在解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650188818","title":"港股异动 | 维立志博-B(09887.HK)涨超5% 维利信™获纳入优先审评审批程序 用于治疗晚期肺外神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650188818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650188818?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:38","pubTimestamp":1783669103,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000500386.USD","BK1161","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134216700","title":"维立志博-B获NMPA优先审评资格　PD-L1/4-1BB双抗维利信™冲刺EP-NEC首款上市药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1134216700","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134216700?lang=zh_cn&edition=full","pubTime":"2026-07-10 12:31","pubTimestamp":1783657890,"startTime":"0","endTime":"0","summary":"2026年7月10日，维立志博-B公布，其自主研发的PD-L1/4-1BB双特异性抗体奥帕替苏米单抗单药用于治疗晚期肺外神经内分泌癌的生物制品上市许可申请，获国家药品监督管理局药品审评中心纳入优先审评审批程序。根据中国现行法规，优先审评BLA的审评时限为130个工作日，较常规200个工作日显著缩短。公司提醒投资者，依据香港联交所证券上市规则第18A.05条，维利信仍处于监管审评阶段，无法保证最终能成功上市。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649988702","title":"【券商聚焦】华源证券首予维立志博(09887)买入评级 看好核心管线潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649988702","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649988702?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:37","pubTimestamp":1783413472,"startTime":"0","endTime":"0","summary":"、研报核心看好公司管线LBL-024成为下一代IO 2.0基石药物的潜力。考虑到公司在肿瘤及自免领域的深度布局及临床管线的有序推进，首次覆盖给予“买入”评级。主要风险包括临床研发失败、竞争格局恶化、销售不及预期及行业政策风险。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985266","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","KCE","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115028409","title":"维立志博-B 2026年6月股份变动月报表，股本总数保持198,891,800股","url":"https://stock-news.laohu8.com/highlight/detail?id=1115028409","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115028409?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:09","pubTimestamp":1782983392,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司于2026年7月2日披露截至2026年6月30日的证券变动月报表。报告期内，公司法定注册股本由期末的人民币198,891,800元保持不变，各类股份总数维持198,891,800股。报告期内，H股由上月底的153,278,691股增加44,391,598股，本月底结存为197,670,289股；未上市股份由上月底的45,613,109股减少44,391,598股，本月底结存1,221,511股。截至2026年6月30日，公司总股本保持为198,891,800股，相关事项均符合适用的法律法规及上市规则。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648154843","title":"维立志博-B(09887)：根据H股奖励计划授出合共225.47万份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2648154843","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648154843?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:17","pubTimestamp":1782908274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2026年7月1日，本公司根据H股奖励计划向149名受让人授出合共225.47万份奖励，惟须待受让人接纳后方可作实。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HK0000500386.USD","BK1161","09887","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646287380","title":"H股全流通、早期股东解禁与存仓异动，腰斩后的维立志博-B(09887)是否值博？","url":"https://stock-news.laohu8.com/highlight/detail?id=2646287380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646287380?lang=zh_cn&edition=full","pubTime":"2026-06-26 09:54","pubTimestamp":1782438888,"startTime":"0","endTime":"0","summary":"同样在4月16日，维立志博-B盘中股价达到97.50港元，创下上市新高。随着其完成H股全流通以及早期股东解禁期即将到来，维立志博能否抵住这轮场内抛压成为投资者关注的焦点。H股全流通、早期股东解禁与存仓异动拉长时间线来看，维立志博股价今年3-4月实现87.71%的涨幅，其核心驱动力来自产品管线突破与市场流动性改善的双重加持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188451308","title":"维立志博宣布合作伙伴Oblenio Bio完成超额认购的6200万美元B轮融资，推进自身免疫疾病三特异性T细胞衔接器Lbl-051进入临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1188451308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188451308?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:43","pubTimestamp":1782384204,"startTime":"0","endTime":"0","summary":"维立志博宣布，其合作伙伴Oblenio Bio成功完成了一轮超额认购的B轮融资，融资额达6200万美元。此次融资将用于推进其针对自身免疫疾病的三特异性T细胞衔接器Lbl-051进入临床开发阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195591415","title":"维立志博-B完成B轮融资，辉瑞风投领投，Deep Track Capital、GV与Aditum Bio跟投","url":"https://stock-news.laohu8.com/highlight/detail?id=1195591415","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195591415?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:42","pubTimestamp":1782384143,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司近日成功完成B轮融资。本轮融资由辉瑞旗下的风险投资部门辉瑞风投领投，Deep Track Capital、GV以及Aditum Bio共同参与投资。维立志博-B是一家专注于肿瘤免疫治疗及自身免疫性疾病领域创新抗体药物研发的生物技术公司。辉瑞风投的领投，结合Deep Track Capital、GV和Aditum Bio等专业投资机构的共同参与，彰显了资本市场对维立志博-B研发平台与技术潜力的高度认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU1894683264.USD","LU1894683348.USD","SG9999001176.USD","IE00BLSP4239.USD","HK0000252152.HKD","LU0225284248.USD","HK0000252160.HKD","LU0234572021.USD","LU1066053197.SGD","LU0225771236.USD","LU0306807586.USD","BK1161","BK4588","IE00B19Z3B42.SGD","SG9999002224.SGD","LU0456855351.SGD","LU1023059063.AUD","IE000M9KFDE8.USD","LU0122379950.USD","LU1057294990.SGD","SG9999001176.SGD","BK4585","BK4581","BK4599","IE00BLSP4452.SGD","LU0306806265.USD","BK4533","IE00B3T34201.USD","LU0985481810.HKD","09887","LU1066051498.USD","LU0321505439.SGD","LU0868494617.USD","LU1883839398.USD","LU2596442595.SGD","BK4568","PFE","BK4550","SG9999003800.SGD","IE00B19Z3581.USD","IE0002270589.USD","LU0321505868.SGD","SG9999011175.SGD","HK0000500386.USD","BK4592","LU0170899867.USD","SG9999013999.USD","SGXZ57979304.SGD","BK4007","IE00BBT3K403.USD","LU0058720904.USD","SG9999002232.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646187973","title":"维立志博-B(09887.HK):Oblenio完成超额认购6200万美元B轮融资，加速LBL-051的临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2646187973","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646187973?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:04","pubTimestamp":1782381842,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185914600","title":"维立志博-B(09887)完成44,391,598股未上市股份转换为H股，已发行股本增至197,670,289股","url":"https://stock-news.laohu8.com/highlight/detail?id=1185914600","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185914600?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:30","pubTimestamp":1780659015,"startTime":"0","endTime":"0","summary":"2026年6月5日，维立志博-B(09887)发布翌日披露报表，宣布公司于2026年6月4日将44,391,598股未上市股份转换为H股。根据公告，这部分转换股份约占转换前公司已发行股本（不包括库存股份）153,278,691股的28.96%，本次变动后，公司于香港联交所上市的H股总数增至197,670,289股。\n同时，公告显示，对应未上市股份数量由原先的45,613,109股降至1,221,511股，此次转换股数占该部分未上市股份变动金额的比例约为97.32%。\n公司在公告中确认已取得董事会正式授权，且相关转换符合所有适用的上市规则与法律法规。公告由联席公司秘书左洪刚签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维立志博-B(09887)完成44,391,598股未上市股份转换为H股，已发行股本增至197,670,289股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":0.0832},{"period":"1month","weight":0.1935},{"period":"3month","weight":-0.2466},{"period":"6month","weight":0.2576},{"period":"1year","weight":0.8414},{"period":"ytd","weight":0.2637}],"compareEarnings":[{"period":"1week","weight":0.0384},{"period":"1month","weight":0.0509},{"period":"3month","weight":-0.0508},{"period":"6month","weight":-0.0542},{"period":"1year","weight":0.0128},{"period":"ytd","weight":-0.019}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}